Methyl protodioscin is a multi-target, selective, steroidal diglycoside inhibitor with antitumor activity that induces cell cycle arrest. It exhibits significant antitumor, anti-inflammatory, and anti-restenosis activities, making it suitable for research on various cancers and inflammatory diseases.
- Induces G2/M cell cycle arrest.
- Regulates Bcl-2/Bax apoptotic pathway.
- Inhibits Akt1/c-Myc axis and MAPK/ERK signaling.
- Reduces cholesterol synthesis by downregulating ADAM15 and inducing FOXO1.
- Inhibits JNK/c-Jun pathway to reduce inflammatory factors.
- Shows potent antitumor effects, including inhibiting proliferation, migration, and invasion.
- Demonstrates anti-inflammatory and anti-restenosis properties.
- Useful in lung, prostate, and pancreatic cancer research.
- Applicable in studies of airway inflammation and enteritis.